GlassScriptPhysician profile
Lourdes D Rodriguez
NPI 1063884047
$17,121.83
in general payments reported to CMS, 2019-2025
53 companies · $4,153 in 2025
The $4,153 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $120 · 2021: $2,404 · 2022: $2,864 · 2023: $3,487 · 2024: $3,989 · 2025: $4,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $501 · Education: $35.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,094.01 |
| Travel and Lodging | $500.59 |
| Education | $35.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,101.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $1,310.68 | 2021-2025 | Minimed 780g, Mio, Minimed 770g |
| Lilly USA, LLC | $1,214.35 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $1,094.96 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $898.81 | 2021-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Radius Health, INC. | $819.02 | 2021-2025 | Tymlos |
| Abbott Laboratories | $803.67 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Amgen INC. | $764.92 | 2021-2025 | Tepezza, Evenity, Prolia |
| Insulet Corporation | $693.03 | 2022-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $622.43 | 2021-2023 | Farxiga |
| Corcept Therapeutics | $589.67 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $585.87 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $515.31 | 2020-2025 | Jardiance, Synjardy, Trijardy Xr |
| Ibsa Pharma INC. | $500.01 | 2021-2025 | Tirosint, Licart, Flector |
| Bayer Healthcare Pharmaceuticals INC. | $460.99 | 2022-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $383.21 | 2020-2025 | Unithroid |
| Abbvie INC. | $343.70 | 2021-2025 | Synthroid |
| Novartis Pharmaceuticals Corporation | $287.80 | 2022-2025 | Leqvio |
| Recordati_rare_diseases_inc. | $273.97 | 2022-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $255.87 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Ascendis Pharma Endocrinology INC | $245.83 | 2024-2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $225.87 | 2021-2025 | Strensiq |
| Nevro Corp. | $203.27 | 2023 | Senza |
| Merck Sharp & Dohme LLC | $197.35 | 2021-2023 | Steglatro, Steglujan |
| Kyowa Kirin, INC. | $194.80 | 2023-2025 | Crysvita |
| Amarin Pharma, INC. | $132.69 | 2021 | |
| Tolmar, INC. | $118.99 | 2024-2025 | Jatenzo |
| Becton, Dickinson and Company | $93.50 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $90.32 | 2025 | |
| Horizon Therapeutics Plc | $86.99 | 2022-2023 | Tepezza |
| Madrigal Pharmaceuticals | $85.77 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.41 | 2021-2023 | Cycloset |
| Ultragenyx Pharmaceutical INC. | $76.26 | 2021-2022 | |
| Sequel Med Tech, LLC | $70.53 | 2025 | Twiist |
| Globus Medical, INC. | $61.96 | 2025 | Senza |
| Kowa Pharmaceuticals America, INC. | $58.12 | 2020-2021 | |
| Pfizer INC. | $53.71 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $51.00 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Halozyme INC | $47.62 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $47.60 | 2025 | Imcivree |
| Chiesi USA, INC. | $47.03 | 2025 | Mycapssa |
| Amryt Pharma Holdings LTD | $41.74 | 2022 | |
| Averitas Pharma INC. | $38.76 | 2023-2025 | Qutenza |
| Soleno Therapeutics, INC. | $33.98 | 2025 | Vykat Xr |
| Zealand Pharma US, INC. | $33.83 | 2021-2022 | |
| Mannkind Corporation | $32.16 | 2022 | |
| Cequr Corporation | $31.24 | 2024-2025 | Cequr Simplicity |
| Biotronik Nro, INC. | $28.67 | 2025 | Prospera |
| Blueprint Medicines Corporation | $23.40 | 2021 | |
| Vistapharm, INC. | $20.94 | 2021 | |
| Acella Pharmaceuticals, LLC | $17.66 | 2025 | NP Thyroid 60 |
| Clarus Therapeutics INC. | $16.64 | 2021 | |
| Eusa Pharma (US) LLC | $14.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lourdes Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.